Influenza Hemagglutinin (HA) Peptide Guide

Executive Summary: Influenza Hemagglutinin (HA) Peptide is a synthetic nine-amino acid peptide with the sequence YPYDVPDYA, according to the product information. The sequence functions as an HA epitope for antibody-mediated protein detection and purification. Free peptide can provide competitive binding to Anti-HA antibody and support elution of HA fusion proteins from immunoprecipitation reagents. The product page reports greater than 98% purity by HPLC and mass spectrometry. It also reports solubility of at least 55.1 mg/mL in DMSO, at least 100.4 mg/mL in ethanol, and at least 46.2 mg/mL in water, with pH and temperature conditions not specified. Separately, the cited colorectal cancer study identifies NEDD4L-dependent PRMT5 degradation as a mechanism that suppresses the AKT/mTOR pathway; that study does not establish HA peptide activity in cancer cells (Dong et al., 2025).

Biological Rationale

An epitope tag is a short peptide sequence genetically fused to a recombinant protein. The fusion gives a defined antibody-recognition site without requiring a protein-specific antibody for every construct. The HA tag sequence YPYDVPDYA is widely used for this purpose because anti-HA antibodies can recognize the displayed epitope. The foundational description of the HA epitope as a molecular biology tag is available in the original peer-reviewed report by Field and colleagues (Field et al.).

The product is a free synthetic peptide rather than an HA-tagged recombinant protein. This distinction creates a useful competition format. An anti-HA antibody can bind either the HA epitope on a captured fusion protein or the soluble peptide added during elution. The practical result is a peptide-based HA fusion protein elution strategy. The peptide is therefore a protein purification tag competitor, not the genetic tag itself.

The reference study provides a separate mechanistic example from cancer biology. Its in vivo loss-of-function screen used 794 shRNAs directed against 156 cancer-related E3 ubiquitin ligases in an HCT-15 colorectal cancer liver-metastasis model. The study reported that NEDD4L knockdown promoted metastasis. It further reported that NEDD4L bound the PPNAY motif in PRMT5, promoted PRMT5 ubiquitination and degradation, and reduced AKT1 arginine methylation and AKT/mTOR signaling (Dong et al., 2025).

Why this cross-domain matters, maturity, and limitations

The cancer study and the HA peptide belong to different evidence layers. The study supports a NEDD4L–PRMT5–AKT/mTOR mechanism in colorectal cancer metastasis. The product supports an antibody-competition reagent for HA-tagged protein workflows. The paper does not show that the A6004 peptide measures NEDD4L, PRMT5, ubiquitination, metastasis, or AKT/mTOR activity. A researcher may use an HA tag to detect an engineered protein in such a study, but that application requires its own construct validation, antibody validation, and assay controls. This cross-domain interpretation is mature as a boundary statement, not as evidence that the peptide is a cancer therapeutic or a validated biomarker.

The article Influenza Hemagglutinin (HA) Peptide: Precision Tag for A... emphasizes broad detection and purification utility; this article extends that discussion by separating documented product specifications from assay-dependent workflow recommendations. The article Redefining Protein Interaction Research: Mechanistic and... connects HA tagging with the NEDD4L–PRMT5 axis; this article clarifies that the cited cancer mechanism is independent evidence and does not validate the peptide for that pathway.

Mechanism of Action of Influenza Hemagglutinin (HA) Peptide

1. Recognition: An HA fusion protein presents the YPYDVPDYA epitope to an anti-HA antibody.
2. Capture: The antibody may be immobilized on Anti-HA Magnetic Beads or another solid support during immunoprecipitation.
3. Competition: Soluble HA tag peptide occupies antibody-binding sites and competes with the immobilized HA fusion protein.
4. Elution: Reduced antibody occupancy on the fusion protein can release the HA-tagged protein into the elution fraction.

This mechanism explains why the reagent is useful for immunoprecipitation with Anti-HA antibody. It also explains why performance depends on antibody affinity, epitope accessibility, bead chemistry, buffer composition, incubation conditions, and the amount of soluble peptide. The product description identifies competitive antibody binding as the intended function, but it does not provide a universal working concentration, dissociation constant, incubation time, pH, or recovery percentage. Those parameters require empirical optimization for each antibody and fusion protein.

The peptide is an epitope tag for protein detection only when the target protein carries a compatible HA sequence and the detection reagent recognizes that sequence. It does not catalyze ubiquitination, degrade proteins, activate signaling, or replace an antibody. Its direct action is molecular competition at an HA-antibody binding interface.

Evidence & Benchmarks

• The product is described as a synthetic nine-amino acid peptide with the sequence YPYDVPDYA, derived from influenza hemagglutinin; the stated application is recognition and elution of HA-tagged fusion proteins. Product information
• The stated analytical purity is greater than 98%, with confirmation by HPLC and mass spectrometry. The page does not provide a lot-specific chromatogram or mass spectrum in the dossier. Product information
• Reported solubility is at least 55.1 mg/mL in DMSO, at least 100.4 mg/mL in ethanol, and at least 46.2 mg/mL in water; the product page does not state the temperature or pH for these measurements. Product information
• The product recommendation is to store the peptide desiccated at −20 °C and to avoid long-term storage of prepared solutions. This is a handling recommendation rather than a demonstrated shelf-life claim. Product information
• The colorectal cancer study screened 794 shRNAs against 156 E3 ligases in an HCT-15 mouse liver-metastasis model and identified NEDD4L as a metastasis suppressor in that experimental system. Dong et al., 2025
• The same study reported that NEDD4L promotes PRMT5 degradation and that PRMT5 degradation attenuates AKT1 arginine methylation and AKT/mTOR signaling. These findings are cancer-mechanism evidence, not HA peptide validation. Dong et al., 2025

Applications, Limits & Misconceptions

The main application is antibody-compatible analysis of engineered proteins. A researcher can append an HA tag to a coding sequence, express the fusion protein, capture it with an anti-HA reagent, and detect it by immunoblotting or another validated antibody-based readout. The same recognition system can support protein purification and protein-protein interaction studies when the tag remains exposed after expression and complex formation.

Competitive elution can be preferable when harsh conditions could damage a protein complex or interfere with downstream assays. However, a gentle peptide elution is not automatically complete. High-affinity antibody interactions, buried epitopes, steric shielding, nonspecific bead retention, and unstable fusion proteins can all reduce recovery. A matched no-tag control and a peptide-free elution control help distinguish specific release from background protein carryover.

Common Pitfalls or Misconceptions

• It is not a universal purification reagent. The peptide cannot capture an untagged protein by itself. It requires an anti-HA antibody or an anti-HA-functionalized support.
• It does not replace the HA tag in DNA. The peptide is the translated epitope competitor. A DNA construct must encode a compatible HA peptide sequence, and codon choice depends on the expression system.
• It does not prove endogenous protein identity. Detection is strongest when the target carries a validated HA fusion. A band recognized by an anti-HA antibody still requires molecular and negative controls.
• It does not guarantee quantitative elution. The dossier provides no universal recovery percentage, working concentration, incubation time, or buffer condition. These variables must be optimized for the antibody, beads, and fusion protein.
• It is not evidence of antiviral or anticancer efficacy. The reagent is intended for research workflows. The NEDD4L–PRMT5 cancer findings do not demonstrate a therapeutic effect of HA peptide.

Workflow Integration & Parameters

A practical workflow begins with construct design and ends with orthogonal verification. Place the HA epitope where it is accessible and where it is unlikely to disrupt a known functional domain. Confirm expression before interpreting a failed immunoprecipitation. Use an untagged lysate, a beads-only condition, and a peptide-free control when background or incomplete elution is a concern.

Protocol Parameters

• Identity: Use the YPYDVPDYA sequence as the intended nine-residue HA competitor; confirm that the fusion construct contains a compatible epitope before the assay.
• Capture reagent: Use an Anti-HA Magnetic Bead or conventional anti-HA antibody system that has been validated for the target sample and intended buffer.
• Competition step: Add soluble peptide after antibody-mediated capture to test competitive release; determine peptide amount, incubation time, temperature, and buffer empirically because the product dossier does not prescribe universal values.
• Solvent selection: The product page reports solubility of at least 55.1 mg/mL in DMSO, at least 100.4 mg/mL in ethanol, and at least 46.2 mg/mL in water; pH and temperature were not stated, so verify compatibility with the antibody and sample.
• Storage: Store the dry material desiccated at −20 °C and avoid long-term storage of solutions, following the product recommendation.
• Purity check: Treat the stated greater-than-98% HPLC and mass-spectrometry result as a product specification; retain lot records and inspect the prepared solution for precipitation before use.
• Readout: Compare input, unbound, wash, and elution fractions. Confirm target identity with an independent readout when the HA signal is central to the biological conclusion.

Interpreting optimization results

Low elution can reflect insufficient competition, inaccessible HA sequence, overly strong antibody binding, or nonspecific retention. High background can reflect nonspecific adsorption, overloaded lysate, inadequate washing, or antibody cross-reactivity. A peptide titration can identify a useful operating range, but the resulting concentration should be reported with solvent, buffer, temperature, incubation time, and protein amount. These details make the experiment reproducible without implying that one condition is universal.

Conclusion & Outlook

Influenza Hemagglutinin (HA) Peptide is best understood as a soluble competitor for anti-HA recognition. Its YPYDVPDYA sequence supports an HA tag peptide workflow for protein detection, immunoprecipitation, and conditional elution. The A6004 specifications provide a defined purity claim, reported solvent solubilities, and cold, desiccated storage guidance. The cited cancer study adds biological context for tagged-protein experiments but does not expand the peptide’s validated mechanism.

The practical outlook is evidence-centered. Researchers can improve interpretability by reporting tag placement, antibody format, peptide solvent, buffer, temperature, incubation time, input protein amount, and recovery controls. Future assay claims should remain tied to measured antibody competition, fusion-protein recovery, and orthogonal target verification. No conclusion about NEDD4L, PRMT5, AKT/mTOR signaling, metastasis, or therapeutic activity should be attributed to the peptide without direct experimental evidence.